News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,923 Results
Type
Article (39146)
Company Profile (283)
Press Release (648494)
Section
Business (203900)
Career Advice (1996)
Deals (35371)
Drug Delivery (89)
Drug Development (80849)
Employer Resources (168)
FDA (16098)
Job Trends (14808)
News (344641)
Policy (32450)
Tag
Academia (2530)
Alliances (49183)
Alzheimer's disease (1259)
Approvals (16057)
Artificial intelligence (144)
Bankruptcy (352)
Best Places to Work (11581)
Biotechnology (200)
Breast cancer (188)
Cancer (1368)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (281)
Clinical research (64694)
Collaboration (483)
Compensation (262)
COVID-19 (2541)
C-suite (108)
Data (1391)
Diabetes (174)
Diagnostics (6170)
Earnings (84893)
Employer resources (146)
Events (110007)
Executive appointments (394)
FDA (16779)
Funding (426)
Gene therapy (195)
GLP-1 (598)
Government (4333)
Healthcare (18693)
Infectious disease (2634)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16339)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7861)
Lung cancer (197)
Lymphoma (98)
Manufacturing (206)
Medical device (13212)
Medtech (13217)
Mergers & acquisitions (19192)
Metabolic disorders (456)
Neuroscience (1579)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1696)
Obesity (259)
Opinion (183)
Patents (117)
People (56458)
Phase I (20120)
Phase II (28493)
Phase III (21238)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (261)
Real estate (5890)
Regulatory (21677)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1460)
Startups (3562)
United States (15162)
Vaccines (563)
Weight loss (182)
Date
Today (29)
Last 7 days (576)
Last 30 days (2279)
Last 365 days (35189)
2024 (35030)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54086)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29264)
2010 (27328)
Location
Africa (713)
Arizona (195)
Asia (37270)
Australia (6088)
California (3812)
Canada (1449)
China (306)
Colorado (171)
Connecticut (177)
Europe (79825)
Florida (535)
Georgia (135)
Illinois (384)
Indiana (225)
Maryland (629)
Massachusetts (2963)
Michigan (173)
Minnesota (290)
New Jersey (1101)
New York (1083)
North Carolina (742)
Northern California (1696)
Ohio (146)
Pennsylvania (923)
South America (1092)
Southern California (1460)
Texas (548)
Utah (108)
Washington State (400)
687,923 Results for "vaxxas inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vaxxas Expands Global Intellectual Property Portfolio for Exclusive Manufacture and Sale of Needle-Free Vaccination Technology
November 25, 2024
·
5 min read
Press Releases
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
October 28, 2024
·
6 min read
Press Releases
Vaxxas Initiates Phase I Clinical Trial of Pre-Pandemic Avian Influenza A Virus (H7N9) Vaccine Delivered Using Vaxxas’ Novel High-Density Microarray Patch (HD-MAP)
September 11, 2024
·
6 min read
Genetown
Vaccine Journal Highlights the Potential for Self-Administration of Vaccines Using Vaxxas High-Density Microarray Patch (HD-MAP)
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced a publication in the journal Vaccine entitled “Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.”
October 18, 2023
·
6 min read
Business
Vaxxas Appoints Rochelle Chaiken, M.D., as Chief Medical Officer
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, announced the appointment of Rochelle Chaiken, M.D., as Chief Medical Officer.
June 5, 2023
·
4 min read
SK bioscience and Vaxxas Enter Joint Development Agreement for Needle-Free Patch Delivery of Typhoid Vaccine
SK bioscience announced that the company has entered into a collaboration agreement with Vaxxas, an Australian biotechnology company developing a unique vaccine patch platform technology, to develop a second-generation typhoid conjugate vaccine with support from Wellcome.
August 23, 2023
·
8 min read
Biotech Bay
Vaxxas Awarded US$3.67 million (AU$5.4 million) from global charitable foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination using Needle-Free Vaccine Patch
Vaxxas announced that the global charitable foundation, Wellcome, has made an award totaling US$3.67 million to conduct IND-enabling studies and a first-in-human clinical study for a potentially second generation typhoid vaccine delivered by Vaxxas’ proprietary high-density microarray patch platform technology.
August 23, 2023
·
8 min read
Drug Development
Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has published positive results from a human clinical trial involving its potentially game-changing technology that enables vaccines to be applied to the skin using a small patch, instead of using traditional needle and syringe.
November 26, 2023
·
6 min read
Biotech Bay
Vaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials and First Commercial Products
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland.
June 18, 2023
·
8 min read
Drug Development
Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP)
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.
June 5, 2023
·
6 min read
1 of 68,793
Next
